Bayer Says Cipla Generic Negates Critics Of Anti-Compulsory License Suit
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Bayer said the argument on its court fight in India to overturn a compulsory-licensing decision allowing Natco Pharma to market a generic of its Nexavar (sorafenib) cancer drug has been obviated by Cipla's launch of another generic.